Citizens Jmp Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock

Posted by Geri Gentry on Jun 9th, 2026

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) had its target price upped by stock analysts at Citizens Jmp to $25.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective would indicate a potential upside of 91.57% from the company’s previous close.

ZVRA has been the subject of several other research reports. Weiss Ratings cut Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, May 22nd. Cantor Fitzgerald upped their price target on Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday. BTIG Research initiated coverage on shares of Zevra Therapeutics in a report on Monday, March 16th. They set a “buy” rating and a $23.00 price objective for the company. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday. Finally, HC Wainwright reissued a “buy” rating on shares of Zevra Therapeutics in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Zevra Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $26.17.

Get Our Latest Report on Zevra Therapeutics

Zevra Therapeutics Price Performance

ZVRA opened at $13.05 on Tuesday. The company has a 50 day simple moving average of $10.37 and a two-hundred day simple moving average of $9.39. The firm has a market cap of $771.52 million, a P/E ratio of 6.49 and a beta of 0.91. Zevra Therapeutics has a 1-year low of $7.16 and a 1-year high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The company had revenue of $36.22 million for the quarter, compared to analysts’ expectations of $31.96 million. Equities analysts anticipate that Zevra Therapeutics will post 0.56 earnings per share for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors have recently modified their holdings of ZVRA. Quantinno Capital Management LP increased its position in shares of Zevra Therapeutics by 114.1% during the 1st quarter. Quantinno Capital Management LP now owns 32,022 shares of the company’s stock valued at $298,000 after purchasing an additional 17,065 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Zevra Therapeutics by 259.2% in the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after buying an additional 400,336 shares during the last quarter. AIGH Capital Management LLC purchased a new position in Zevra Therapeutics during the first quarter worth $11,184,000. Simplify Asset Management Inc. increased its position in Zevra Therapeutics by 137.5% during the first quarter. Simplify Asset Management Inc. now owns 100,630 shares of the company’s stock valued at $938,000 after acquiring an additional 58,265 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its stake in shares of Zevra Therapeutics by 16.7% in the first quarter. Janney Montgomery Scott LLC now owns 236,834 shares of the company’s stock valued at $2,207,000 after acquiring an additional 33,951 shares during the period. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

(Get Free Report)

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.